Journal article
40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy
Authors
Biziotis O-D; Tsakiridis E-E; Broadfield L; Farrell T; Menjolian G; Mathurin T; Mekhaeil B; Zacharidis P; Muti P; Abdulkarim B
Journal
Radiotherapy and Oncology, Vol. 139, ,
Publisher
Elsevier
Publication Date
10 2019
DOI
10.1016/s0167-8140(19)33327-4
ISSN
0167-8140